Abstract
• COVID-19 can present with delayed onset of symptoms in patients with lymphoma receiving rituximab-based chemoimmunotherapy. • Despite delayed onset of symptoms with prolonged asymptomatic period, outcomes can be particularly severe, including respiratory failure, thrombotic complications, and death.
| Original language | English (US) |
|---|---|
| Pages (from-to) | e548-e550 |
| Journal | Clinical Lymphoma, Myeloma and Leukemia |
| Volume | 21 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2021 |
Keywords
- COVID-19
- Chemotherapy
- Rituximab
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Divisions
- Medical Oncology
Fingerprint
Dive into the research topics of 'Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS